Cimarex Energy Co (XEC) Falls 3.8% for February 02

Equities Staff |

One of the S&P 500’s big losers for Tuesday February 02 was Cimarex Energy Co (XEC). The company’s stock fell 3.8% to $83.92 on volume of 1.19 million shares.

The stock opened the day at 84.29 and traded between a low of $83.69 and a high of $86.46. The stock finished the day down $3.315 per share. Cimarex Energy Co has an average daily volume of 1.42 million and a total float of 94.56 million shares. The 50-day SMA for Cimarex Energy Co is $96.40 and its 200-day SMA is $108.65. The high for the stock over the last 52 weeks is $132.18 and the low is $72.77.

Cimarex Energy Co is an oil and gas exploration and production company with operations in two main areas: the Mid-Continent region and the Permian Basin.

Cimarex Energy Co is centered in Denver, CO, and has 991 employees. Today’s trading day leaves the company with a market cap of $7.93 billion. The company has a P/S ratio of n/a, P/B ratio of 2.31, and a -32.4.

For a complete fundamental analysis analysis of Cimarex Energy Co, check out Equities.com’s Stock Valuation Analysis report for XEC. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

The S&P 500 represents the industry standard for large-cap indices. While the Dow Jones Industrial Average (DJIA) may be the most visible stock market index in the country, the S&P 500 has long been relied on by industry insiders and fund managers as the more reliable gauge of portfolio performance.

While the DJIA is price-weighted and only includes 30 stocks, the S&P 500 uses a weighting system that factors in market cap and the size of a company’s free float while including some 500 stocks for a more comprehensive look at the broader markets’ performance. Its performance is far more representative of the large- and mega-cap stocks for any period of time.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Emerging Growth

Beleave Inc.

Beleave Inc is a biotech company. The Company is engaged in the production of medical marijuana under the Marihuana for Medical Purposes Regulations outlined by Health Canada.

Private Markets

Snapwire

A peer-to-Peer authentic photo marketplace disrupting the $10B commercial photography industry.

Cross Campus

With over 500 members and operating 80,000 square feet by summer 2016, Cross Campus is one of the country’s top ten shared, collaborative office or "coworking" operators in the US.…